Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Heading 4
Fanhdi 250 IU Injection
Manufacturer/Marketed By : Grifols India Healthcare Private Limited
$44.31 $32.94
Fanhdi 250 IU Injection is a specialized treatment option for individuals suffering from hemophilia A, a genetic disorder characterized by a deficiency in Factor VIII, which is crucial for blood...
Collapsible text is perfect for longer content like paragraphs and descriptions. It's a great way to give people more information while keeping your layout clean. Link your text to anything, including an external website or a different page. You can set your text box to expand and collapse when people click, so they can read more or less info.
Human Anti Haemophilic Factor Vill 250 IU
Active Pharmaceutical Ingredient
Fanhdi 250 IU Injection
44,31$
32,94$
Fanhdi 250 IU Injection is a specialized treatment option for individuals suffering from hemophilia A, a genetic disorder characterized by a deficiency in Factor VIII, which is crucial for blood clotting. This injectable medication, derived from human plasma, plays a vital role in both preventing and controlling bleeding episodes, particularly during surgical procedures, whether emergency or elective, for both adults and children. By replenishing the deficient antihemophilic factor, Fanhdi helps restore normal clotting ability, significantly reducing the risk of excessive bleeding. It is important to note that this product is not suitable for treating von Willebrand disease, a related bleeding disorder caused by inadequate levels of a specific clotting protein. Patients should be aware of potential side effects, including common reactions, and should consult healthcare professionals for proper administration and monitoring. As with any medication, it is essential to discuss any pre-existing health conditions or allergies with a healthcare provider before use. Fanhdi 250 IU Injection is a reliable choice for managing hemophilia A and enhancing the quality of life for those affected by this condition.
Active Pharmaceutical Ingredient
Uses
• Fanhdi 250 iu injection is primarily used to manage bleeding episodes in patients diagnosed with hemophilia A. This inherited disorder arises from a deficiency in coagulation factor VIII, leading to inadequate blood clotting. By providing the necessary factor VIII, Fanhdi 250 iu injection helps control bleeding, allowing patients to lead a more active life. It is crucial in preventing spontaneous bleeds that can occur in these individuals.
• In addition to managing acute bleeding, Fanhdi 250 iu injection is instrumental during surgical procedures for patients with hemophilia A. Proper blood clotting is vital during surgery, and the administration of this injection ensures that the patient's blood can clot effectively. By using Fanhdi 250 iu injection, healthcare providers can minimize the risks associated with surgery in hemophilic patients. This preparation helps facilitate safer surgical outcomes.
• Fanhdi 250 iu injection is also utilized as a preventive measure in patients with hemophilia A who engage in physical activities. Individuals with this condition are at a higher risk of bleeding during exercise or sports. By administering Fanhdi 250 iu injection before such activities, it helps to reduce the likelihood of bleeding episodes. This proactive approach allows patients to participate in physical activities with greater confidence and safety.
• Another important application of Fanhdi 250 iu injection is in the treatment of bleeding complications in patients undergoing dental procedures. Dental work can pose a significant risk for individuals with hemophilia A due to their impaired clotting ability. The use of Fanhdi 250 iu injection prior to these procedures helps to ensure adequate clot formation and minimize the risk of excessive bleeding. This application emphasizes the importance of tailored care for hemophilic patients during routine healthcare.
Benefits
Prevents or Controls Bleeding In Patients With Hemophilia A: The use of Fanhdi 250 IU Injection has proven to be effective in addressing the deficiency of circulating factor VIII in patients with haemophilia A, a sex-linked hereditary disorder of blood coagulation. This disorder causes a decrease in the level of factor VIII, resulting in excessive bleeding into joints, muscles, or internal organs. Whether it occurs spontaneously or due to accidental or surgical trauma, Fanhdi 250 IU Injection has demonstrated its ability to prevent or control such bleeding.
Side Effects
As with all medicines, Fanhdi 250 IU Vial may have side effects which do not require medical attention and which will disappear as your body adjusts to the medicine. Tell your doctor if they persist or if you're worried about them.
Most Common Side Effects
• chills
• Flushing
• Generalised urticaria
• Hives
• Hypotension
• Lethargy
• Restlessness
• Tachycardia
• Tightness of the chest
• Tingling
• Vomiting
• Wheezing
Common Side Effects
• Nervousness
• Headache
• Abdominal pain
• Nausea
• Paresthesia
• Blurred vision
• Angioedema
• Burning and stinging at the infusion site
How To Use
A doctor or nurse will give you Fanhdi Injection in a hospital or clinic. It is important that you always follow your doctor's advice about the timing of your injection. The dose and frequency of administration will depend on the purpose of your treatment. You may also be given other medicines as part of your treatment. It is important that you take all of your medicine for the full prescribed time.
Safety Advice
• Alcohol: Consumption of alcohol is not recommended while using Anti-hemophilia Drug Fanhdi. Alcohol may increase or decrease the effectiveness of the medicine and also increase the risk of side effects. It is the best advice for you before consuming alcohol, you can talk with a doctor or pharmacist, and they will tell you consumption of alcohol is safe or not.
• Kidney: No information is not avaliable for this medicine used in kidney disease patients. Please consult your doctor before using this Fanhdi 250 IU.
• Breastfeeding: Fanhdi 250 IU Injection should be given to breastfeeding mothers only if clinically indicated. The safety of this medicine used in breastfeeding mothers has not been established. It is not known whether this drug is excreted into human milk. Physicians should carefully consider the potential risks and benefits for each specific patient before prescribing Fanhdi Injection.
• Liver: No information is not avaliable for this medicine used in liver disease patients. Please consult your doctor before using this Human Anti Haemophilic Factor VIII Injection 250 IU.
• Pregnancy: Fanhdi 250 IU Injection should be given to a pregnant woman only if clearly needed. Animal reproduction studies have not been conducted with Fanhdi Injection. The safety of this medicine use in pregnant women has not been established. It is not known whether Human Anti Haemophilic Factor VIII Injection 250 IU can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
• Driving: Human Anti Haemophilic Factor VIII Injection 250 IU will not affect your ability to drive or operate machinery. In case you experience any side effects while taking Fanhdi 250 IU such as dizziness or drowsiness, it is important to avoid driving or operating heavy machinery until the side effects have resolved.
Disclaimer
Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.
All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.
Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.